Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $300,381 - $402,829
99,464 Added 187.93%
152,389 $463,000
Q2 2023

Aug 14, 2023

BUY
$2.79 - $5.03 $147,660 - $266,212
52,925 New
52,925 $174,000
Q3 2022

Nov 14, 2022

SELL
$3.75 - $7.39 $571,905 - $1.13 Million
-152,508 Reduced 69.27%
67,646 $428,000
Q2 2022

Aug 15, 2022

BUY
$2.94 - $5.23 $549,127 - $976,848
186,778 Added 559.62%
220,154 $911,000
Q1 2022

May 16, 2022

SELL
$4.07 - $10.6 $237,867 - $619,506
-58,444 Reduced 63.65%
33,376 $162,000
Q4 2021

Feb 14, 2022

BUY
$8.96 - $16.31 $822,707 - $1.5 Million
91,820 New
91,820 $917,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $485M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.